14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
PLYX vs SER: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SER Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 6–1 Matrix Metrics)
SER Overall Winner
6-Pillar Tally: PLYX 0 – 3 SER (3 Tie)
Matrix Metrics: PLYX 1 – 6 SER
As of Nov 19, 2026, Serina Therapeutics, Inc. (SER) is the stronger overall head-to-head candidate over PLYX (PLYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PLYX carries a Unified Composite Score of 43.3/100 (HOLD) at $1.51 (N/M Forward P/E, N/A operating margin), whereas SER carries 43.1/100 (HOLD) at $1.20 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: PLYX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.3); meanwhile SER is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLYX vs SER. Trailing 12-month operating profitability (PLYX N/A vs SER 0.0%) and valuation multiples (PLYX N/M vs SER N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
SER Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $35.9M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PLYX vs SER Key Questions & Quantitative Answers
As of Nov 19, 2026, Serina Therapeutics, Inc. (SER) is the stronger overall head-to-head candidate over PLYX (PLYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PLYX carries a Unified Composite Score of 43.3/100 (HOLD) at $1.51 (N/M Forward P/E, N/A operating margin), whereas SER carries 43.1/100 (HOLD) at $1.20 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PLYX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.3); meanwhile SER is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SER leads the Growth & Scale pillar: PLYX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SER at +154.9% YoY revenue growth and -43.5% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PLYX generates N/A in USD-normalized revenue versus N/A for SER. In operating R&D and SG&A reinvestment, PLYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SER.
PLYX and SER trade at balanced relative valuation multiples. PLYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SER trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLYX (N/A ROE) versus SER (-207.9% ROE) capital efficiency.
In options market volatility and institutional positioning, PLYX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.43β · 60% Vol realized risk). By comparison, SER carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.